{"entity":{"id":"nct07332455","kind":"trial","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","aka":[],"tldr":"A phase 1/2 trial of GSK5471713 in prostate cancer, run by GlaxoSmithKline, now recruiting.","summary":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC is a phase 1/2 interventional study registered as NCT07332455 by GlaxoSmithKline, with 54 participants planned, started 2026-02-10 and due to reach its primary completion in 2028-03-24. Interventions recorded: GSK5471713.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07332455","url":"https://clinicaltrials.gov/study/NCT07332455"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07332455","phase":"1/2","setting":"A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"GlaxoSmithKline","enrolled":54,"outcomes":[]},"route":"/trials/nct07332455/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}